- Sensitive – measure as little as 0.92 pM of APP ΔC31
- Quantitative – fully quantitative results surpass semi-quantitative Western blot analysis
- Higher Throughput – results from up to 38 samples in duplicate in just 2 hours
- Specific – low cross-reactivity to similar APP isoforms
- AMP'D® Certified – obtain more reliable analysis of samples with low APP ΔC31 concentrations with a 10-fold increase in sensitivity (from 0.92 pM to 0.094 pM)
The APP ΔC31 ELISA kit is a complete, colorimetric, immunometric immunoassay kit for the quantitative determination of human APP ΔC31 in cell lysate and cerebral spinal fluid samples with results in just 2 hours. The kit provides a simple and easy-to-use way for the specific measurement of the neo-APP fragment from the APP ΔC31 cleavage event which when combined with measurements of other Alzheimer's disease associated proteins (Aβ40/42, sAPPα and tau/p-tau) could prove a useful biomarker for the diagnosis and monitoring of Alzheimer's disease progression.
Specificity experiment by ELISA and Western blot analysis demonstrates both methods are in agreement and indicate sensitive detection of the APP ΔC31 form with no recognition of APP-695.
Inhibition experiment by ELISA and Western blot analysis indicates both methods are in agreement using treatment of increasing concentrations of caspase inhibitor which reduces the production of APP ΔC31.
Inhibition experiment by ELISA and Western blot analysis indicates both methods are in agreement using treatment of increasing concentrations of caspase inhibitor which reduces the production of APP ΔC31.
Please mouse over
Product Details
| Alternative Name: | Amyloid precursor protein, APP neo |
| |
| Sensitivity: | 0.92 pM (range 11.72 - 1500 pM) |
| |
| Assay Time: | ~2 hours |
| |
| Applications: | ELISA, Colorimetric detection
|
| |
| Application Notes: | For the quantitative determination of human APP ΔC31 in cell lysate, cerebral spinal fluid, plasma and serum samples. Sequence alignments indicate multiple species are probable. |
| |
| Wavelength: | 450 nm |
| |
| Species reactivity: | Human
|
| |
| Use/Stability: | Store all components at +4°C, except standard at -20°C. |
| |
| Shipping: | Blue Ice Not Frozen |
| |
| Contents: | Microtiter Plate, Assay Buffer, Standard, Detector Antibody, Antibody-HRP-conjugate, TMB Substrate, Stop Solution, Wash Buffer Concentrate |
| |
| Scientific Background: | Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the senile plaques, neurofibrillary tangles and loss of synapses and neurons. AD has been largely viewed as a disease of toxicity being mediated by the accumulation of the amyloid beta (Aβ) peptide as plaques within the brain resulting in damage to brain cells from the binding of damaging metals, reactive oxygen species production and direct damage to cellular membranes. Recent research has suggested that the Aβ peptide is a multifunctional peptide with non-pathological effects and that its association with AD is in conjunction with its roles in combination with other proteins such as the amyloid precursor protein (APP) resulting in the imbalance between the processes of memory formation and normal forgetting. It is through the interactions of the Aβ peptide with APP that the Aβ peptide itself can affect normal modulation and signaling of APP resulting in its indicated role in the pathogenesis of AD via signaling effects rather than chemical or physical effects.
There are three major APP isoforms (APP695, APP751 and APP770) that are formed through alternative splicing of precursor mRNA. APP770 represents the canonical sequence. The APP695 isoform is preferentially expressed in the central nervous system, while APP770 and APP751 are more highly expressed in peripheral tissues. It has been demonstrated that the full length APP695 can be cleaved via caspase at an intracellular site (Asp664) resulting in the release of a 31 amino acid C-terminal peptide (C31) from the remaining larger neo-APP fragment (APP ΔC31) with both of these entities being pro-apoptotic. Immunohistochemical analysis of human brain tissue demonstrated that this cytoplasmic cleavage occurs 4-fold greater in patients with AD versus normal patients and that these cleavage products are localized to plaques and tangles in key areas of the brain affected by the disease. A single genetic mutation of aspartic acid residue 664 to alanine of APP695 led to the complete blockage of the C-terminal cleavage in vivo reversing many characteristics of the AD phenotype in a transgenic mouse model. Additionally, in cell culture it has been suggested that the neurotoxicity of Aβ is dependent on the cleavage of APP at Asp664 and the resulting Aβ-facilitated APP multimerization. |
| |
| Technical Info/Product Notes: | Application Notes
A Colorimetric ELISA for Alzheimer’s Disease Research Enabling Quantification of APP ΔC31 in Cell Lysates and Cerebrospinal Fluid
Automation of the Enzo APP ΔC31 ELISA kit |
| |
| UniProt ID: | P05067 |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
| Compatibility: | This product is compatible with the Absorbance 96 Plate Reader.
 |
| |
Product Literature References
Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production: K.S. Poksay, et al.; Front. Pharmacol.
8, 46 (2017),
Abstract;
Full Text
Related Products
